A number of other brokerages have also issued reports on HZNP. BidaskClub raised Horizon Pharma PLC from a hold rating to a buy rating in a research report on Saturday, June 24th. Cantor Fitzgerald set a $13.00 target price on Horizon Pharma PLC and gave the company a buy rating in a research report on Monday, July 31st. Zacks Investment Research raised Horizon Pharma PLC from a sell rating to a hold rating in a research report on Friday, August 11th. UBS AG set a $16.00 target price on Horizon Pharma PLC and gave the company a buy rating in a research report on Tuesday, August 8th. Finally, Mizuho reissued a hold rating and issued a $12.00 target price (up previously from $9.00) on shares of Horizon Pharma PLC in a research report on Monday, August 28th. Five analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of $19.69.
Horizon Pharma PLC (NASDAQ:HZNP) traded up 1.88% during midday trading on Friday, hitting $14.09. The company had a trading volume of 1,347,698 shares. Horizon Pharma PLC has a 52 week low of $9.45 and a 52 week high of $21.98. The stock has a 50 day moving average price of $12.84 and a 200 day moving average price of $13.13. The company’s market capitalization is $2.30 billion.
Horizon Pharma PLC (NASDAQ:HZNP) last announced its earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.29. The company had revenue of $289.51 million for the quarter, compared to analyst estimates of $237.01 million. Horizon Pharma PLC had a positive return on equity of 22.85% and a negative net margin of 42.40%. The firm’s quarterly revenue was up 12.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.56 earnings per share. Equities analysts forecast that Horizon Pharma PLC will post $1.09 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This story was published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.themarketsdaily.com/2017/09/11/horizon-pharma-plc-hznp-given-a-18-00-price-target-by-piper-jaffray-companies-analysts.html.
Several hedge funds have recently modified their holdings of HZNP. Bank of Montreal Can grew its stake in shares of Horizon Pharma PLC by 16.3% during the second quarter. Bank of Montreal Can now owns 9,809 shares of the biopharmaceutical company’s stock worth $116,000 after purchasing an additional 1,378 shares in the last quarter. Sheaff Brock Investment Advisors LLC grew its stake in shares of Horizon Pharma PLC by 5.0% during the second quarter. Sheaff Brock Investment Advisors LLC now owns 10,500 shares of the biopharmaceutical company’s stock worth $125,000 after purchasing an additional 500 shares in the last quarter. Family Management Corp acquired a new position in Horizon Pharma PLC in the second quarter valued at $131,000. Ballentine Partners LLC acquired a new position in Horizon Pharma PLC in the second quarter valued at $139,000. Finally, Massachusetts Financial Services Co. MA acquired a new position in Horizon Pharma PLC in the first quarter valued at $151,000. Hedge funds and other institutional investors own 82.30% of the company’s stock.
About Horizon Pharma PLC
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.